SHTDF News and Press, Sinopharm Group Co. Ltd. From 03/28/23

2023-03-28 12:05:00 ET The World Health Organization (WHO) issued revised recommendations for prioritizing the use of COVID-19 vaccines on Tuesday, including healthy children and adolescents in a low-priority group for immunizations. The announcement follows a meeting of the agency&...

China National Biotec Group (CNBG) a subsidiary of Sinopharm Group ( OTCPK:SHTDF ) ( OTCPK:SHTDY ), announced Friday that authorities in China greenlighted clinical trials for the country's first mRNA-based COVID-19 vaccine targeting the Omicron variant. China's National Medical Produ...

Summary We may not be at the end credits for COVID-19 virus. Shares of Vaxxinity, Inc., like most biotechs, have plummeted over the past year due to unprecedented market headwinds, both macroeconomic and geopolitical. In the meantime, the company has been taking care of its COVID-19...

Merck ( NYSE: MRK ) said it will take legal action against certain pharma companies after it found that some firms were supplying COVID-19 medicine to certain Chinese provinces and cities stating that the therapies were authorized by Merck, Reuters reported . Merck, however, did n...

Qiming Venture Partners closed two new China healthcare and technology funds with $3.2 billion in fresh capital, both of them at their hard cap limits. Suzhou CStone Pharma announced that Gavreto® (pralsetinib) was approved in Hong Kong to treat adult patients with RET fusion-pos...

China National Pharmaceutical Group, also known as Sinopharm ( OTCPK:SHTDY ) ( OTCPK:SHTDF ), is among entities exploring a potential acquisition of China-based DNA synthesis product provider BBI Life Sciences which could be valued over $1B, Bloomberg News reported...

Life sciences company ChromaDex Corporation (NASDAQ:CDXC) announced an agreement with Sinopharm Xingsha, the health supplement division of Sinopharm Group (OTCPK:SHTDF) (OTCPK:SHTDY) on Friday to speed up sales of its anti-aging compound Tru Niagen in China. Tru Niagen is currently available ...

Sinovac Biotech's (NASDAQ:SVA) Omicron-specific vaccine was approved for clinical trials in Hong Kong. Sinovac, a unit of Sinopharm Group (OTCPK:SHTDF) (OTCPK:SHTDY), said preclinical studies showed that the SINOVAC Omicron variant inactivated vaccine was safe and eff...

A group of global institutions led by the International Monetary Fund (IMF) has proposed $15 billion in grants this year and $10 billion annually thereafter as part of a global strategy to address the long-term risks of COVID-19. The IMF, in partnership with the Coalition for Epidemic Prepare...

RemeGen, a Yantai biotech with a deep portfolio of antibody and dual therapies, completed a $410 million IPO on the Shanghai Star Exchange. Nanjing Biosion out-licensed global rights (ex-China) to Pyxis Oncology for an immunotherapy aimed at solid tumor cancers in a $226 million agree...